Company Overview
| Stock Name | Aim Vaccine |
|---|---|
| Stock Code | 06660 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國第二大疫苗公司,涵蓋從研發、製造到商業化的整個價值鏈,已商業化八款針對六個疾病領域的疫苗產品,並擁有22款在研疫苗。 |
| Listing Date | 2022-10-06 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京市大興區瀛海鎮鎮區瀛順路16號興海大廈二層218室 |
| Business Address (Hong Kong) | 香港九龍觀塘道348號宏利廣場5樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | aimbio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 16.16 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,232 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-09-23 to 2022-09-28 |
| Global Offering Shares | 9,714,000 shares |
| HK Public Offer Shares (Initial) | 971,600 shares (10.0%) |
| Public Offer Lots (Initial) | 4,858lots (Pool A2,429lots,Pool B2,429lots) |
| International Placing Shares (Initial) | 8,742,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,209,713,999 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 156,978,240 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,232 |
| 2 lots | 400 | HK$ 6,464 |
| 3 lots | 600 | HK$ 9,696 |
| 4 lots | 800 | HK$ 12,928 |
| 5 lots | 1,000 | HK$ 16,160 |
| 6 lots | 1,200 | HK$ 19,392 |
| 7 lots | 1,400 | HK$ 22,624 |
| 8 lots | 1,600 | HK$ 25,856 |
| 9 lots | 1,800 | HK$ 29,088 |
| 10 lots | 2,000 | HK$ 32,320 |
| 15 lots | 3,000 | HK$ 48,480 |
| 20 lots | 4,000 | HK$ 64,640 |
| 25 lots | 5,000 | HK$ 80,800 |
| 30 lots | 6,000 | HK$ 96,960 |
| 35 lots | 7,000 | HK$ 113,120 |
| 40 lots | 8,000 | HK$ 129,280 |
| 45 lots | 9,000 | HK$ 145,440 |
| 50 lots | 10,000 | HK$ 161,600 |
| 100 lots | 20,000 | HK$ 323,200 |
| 150 lots | 30,000 | HK$ 484,800 |
| 200 lots | 40,000 | HK$ 646,400 |
| 250 lots | 50,000 | HK$ 808,000 |
| 300 lots | 60,000 | HK$ 969,600 |
| 400 lots | 80,000 | HK$ 1,292,800 |
| 500 lots | 100,000 | HK$ 1,616,000 |
| 600 lots | 120,000 | HK$ 1,939,200 |
| 900 lots | 180,000 | HK$ 2,908,800 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,429 lots | 485,800 | HK$ 7,850,528 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.1B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +787% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 19,548,978,223 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 7,931,733,793 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 2021年虧損人民幣675.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 951,648 | 1,637,970 | 1,570,129 |
| Cost of sales | -218,803 | -283,882 | -275,429 |
| Gross profit | 732,845 | 1,354,088 | 1,294,700 |
| Other income and gains, net | 26,163 | 40,714 | 53,622 |
| Selling and distribution expenses | -330,009 | -533,249 | -460,114 |
| Administrative expenses | -157,181 | -198,697 | -1,167,979 |
| Operating profit | 167,542 | 501,627 | -596,000 |
| Net finance costs | -10,781 | -15,741 | -10,703 |
| Profit before tax | 156,761 | 485,886 | -606,703 |
| Income tax expense | -36,947 | -85,472 | -69,170 |
| Profit for the year | 119,814 | 400,414 | -675,873 |
| Profit attributable to owners | 117,406 | 379,287 | -692,774 |
Balance Sheet
| Item | 2019 | 2020 | 2021 | 2022-04 |
|---|---|---|---|---|
| Cash and cash equivalents | 318,639 | 1,102,830 | 646,742 | |
| Trade and bills receivables | 444,838 | 869,864 | 1,063,653 | |
| Inventories | 228,816 | 252,713 | 367,397 | |
| Total current assets | 1,346,308 | 2,438,458 | 2,358,684 | |
| Total assets | 2,950,722 | 4,687,953 | 8,072,353 | |
| Total current liabilities | 1,190,969 | 1,130,969 | 1,570,042 | |
| Total liabilities | 1,332,598 | 1,266,328 | 2,373,063 | |
| Total equity | 1,618,124 | 3,421,625 | 5,699,290 | |
| Equity attributable to owners | 1,539,327 | 3,421,625 | 4,892,595 | |
| Interest-bearing borrowings | 283,630 | 173,725 | 591,698 | 933,250 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 | 2022-04 |
|---|---|---|---|---|
| Net cash from operating activities | 327,012 | 250,331 | 93,398 | |
| Net cash from investing activities | -340,196 | -604,917 | -1,337,505 | |
| Depreciation of PP&E | 63,437 | 72,506 | 87,430 | 32,194 |
| Depreciation of right-of-use assets | 12,171 | 21,940 | 23,071 | 8,559 |
| Amortisation of intangible assets | 33,832 | 33,896 | 33,790 | 11,283 |
| Purchase of PP&E | -314,781 | -666,683 | -1,125,381 | -313,219 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 16.66 |
|---|---|
| First Day Open | HK$ 15.0 |
| First Day Change | -83.79% |
| First Day Volume | 1170400.0 |
| First Day Turnover | 18432000.0 |
| Use of Proceeds | 1、約60%或42.00百萬港元將分配用于推進我們在研疫苗的研發及持續豐富我 們的疫苗管線;
2、約35%或24.50百萬港元將用于為建設新生產設施的資本開支提供資金;
3、約5%或3.51百萬港元將投入我們的銷售及營銷活動以鞏固及擴大市場領導 地位。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (4)
Joint Bookrunners (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
中信建投(国际)融资有限公司 CE BAU112
MACQUARIE CAPITAL LIMITED CE AAC534
BOCI ASIA LIMITED CE AET863
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
招银国际融资有限公司 CE AVM940
富途证券国际(香港)有限公司 CE AZT137
老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (10)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
中信建投(国际)融资有限公司 CE BAU112
MACQUARIE CAPITAL LIMITED CE AAC534
BOCI ASIA LIMITED CE AET863
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
招银国际融资有限公司 CE AVM940
富途证券国际(香港)有限公司 CE AZT137
老虎证券(香港)环球有限公司 CE BMU940
Livermore Holdings Limited CE BJN764
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 周延 | — |
| Company Secretary | 劉靈、林穎芝 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 周延先生直接持有200,000,000股內資股(16.67%),並通過西藏赤誠之心及眾人行持有額外權益;西藏赤誠之心持有200,000,000股內資股;西藏盈豐持有44,300,000股內資股及55,700,000股H股。 |
|---|




